Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246738 · ClinicalTrials.gov registry record
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 87
- Enrollment target
NCT02246738 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 87 participants.
The verdict
NCT02246738 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 87 participants
- Enrollment target
Study Summary
Purposes are to determine whether various cohorts of bladder cancer patients have detectable tCTC's, determine it tCTC levels vary with the natural history of bladder cancer and to see if tCTC's provide novel information.Study population are various cohorts of patients diangosed with urothelial carcinoma of the bladder.Procedures include a venous blood draw, up to two times, over a 6 month period for collection of tCTC's. Up to 15 mL's of blood will be collected at each blood draw.
Interventions
- OTHER Blood Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-08 |
| Est. Completion | 2020-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02246738
The ClinicalTrials.gov registry entry for NCT02246738 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Collection is the first listed.
NCT02246738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02246738 about?
NCT02246738 is a clinical study titled "Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts". Purposes are to determine whether various cohorts of bladder cancer patients have detectable tCTC's, determine it tCTC levels vary with the natural history of bladder cancer and to see if tCTC's provide novel information.Study population are various cohorts of patients diangosed with urothelial carc...
What is the current status of trial NCT02246738?
This trial is currently completed. The enrollment target is 87 participants. The study started on 2014-08. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02246738?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT02246738?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.